Windel Plus (Salbutamol & Ipratropium)
Therapeutic Group: Respiratory » Anti Asthmatics » Bronchodilator
Windel® Plus: Each ampoule contains 2.5 ml isotonic, clear solution for inhalation of salbutamol sulphate BP equivalent to Salbutamol 2.5 mg and Ipratropium Bromide BP equivalent to Ipratropium 0.5 mg.
Windel Plus contains two active bronchodilating substances, Salbutamol Sulphate and Ipratropium Bromide. Salbutamol Sulphate is a beta2-adrenergic agent which acts on airway smooth muscle resulting in relaxation. Salbutamol relaxes all smooth muscle from the trachea to the terminal bronchioles and protects against all bronchoconstrictor challenges. Ipratropium Bromide is a quaternary ammonium compound with anticholinergic properties. In preclinical studies, it appears to inhibit vagally mediated reflexes by antagonising the action of acetylcholine, the transmitter agent released from the vagus nerve. Anticholinergics prevent the increase of intracellular concentration of cyclic guanosine monophosphate (cyclic GMP) caused by interaction of acetylcholine with muscarinic receptors on bronchial smooth muscle. The bronchodilation following inhalation of Ipratropium Bromide is primarily local and site specific to the lung and not systemic in nature. Windel Plus provides the simultaneous release of Ipratropium Bromide and Salbutamol allowing the synergistic efficacy on the muscarinic and beta2-adrenergic receptors in the airways to cause bronchodilation which is superior to that provided by each single agent and with no potentiation of adverse events.
Windel Plus is indicated for the treatment of reversible bronchospasm associated with obstructive airway diseases in patients who require more than a single bronchodilator.
Dosage & Administration
Windel Plus inhalation solution in ampoule may be administered from a suitable nebuliser or an intermittent positive pressure ventilator.
Adults (including elderly): One ampoule as required for the relief of symptoms or as directed. Up to three to four ampoules daily.
Patients should be advised to consult a doctor or the nearest hospital immediately in the case of acute or rapidly worsening dyspnoea if additional inhalations do not produce an adequate improvement.
Adverse Effects: In common with other beta-agonists containing products, side effects of Windel Plus can include fine tremor of skeletal muscles and nervousness and less frequently, tachycardia, dizziness, palpitations or headache, especially in hypersensitive patients.
Potentially serious hypokalaemia may result from prolonged and / or high dose beta2-agonist therapy.
As with use of other inhalation therapy, cough, local irritation and, less commonly, inhalation induced bronchospasm can occur.
As with other beta-mimetics, nausea, vomiting, sweating, weakness and myalgia/muscle cramps may occur. In rare cases decrease in diastolic blood pressure, increase in systolic blood pressure, arrhythmias, particularly after higher doses, may occur.
In individual cases psychological alterations have been reported under inhalation therapy with beta-mimetics.
The most frequent non-respiratory anticholinergic related adverse events are dryness of mouth and dysphonia.
There have been isolated reports of ocular complications (i.e. mydriasis, increased intraocular pressure, angle-closure glaucoma, and eye pain) when aerosolised ipratropium bromide either alone or in combination with adrenergic beta2-agonist, has escaped into the eyes. Ocular side effects, gastrointestinal motility disturbances and urinary retention may occur in rare cases and are reversible.
The combination of Salbutamol & Ipratropium Bromide is contraindicated in patients with hypertrophic obstructive cardiomyopathy and tachyarrhythmia and in patients with a history of hypersensitivity to atropine or its derivatives, or to any other component of the product.
Use in Pregnancy & Lactation
Although there is little published evidence of the safety of combination of Salbutamol & Ipratropium Bromide in the early stages of pregnancy, the individual active ingredients, Ipratropium Bromide and Salbutamol have been in widespread use for many years. No suspect teratogenic factors have been observed in general practice or clinical studies. As a general precaution, however, Windel Plus should only be used in pregnancy and during the lactation period if the expected benefit to the mother is greater than any possible risk to the child.
Windel Plus should be used with caution before childbirth in view of Salbutamol's inhibitory effects on uterine contractions.
Salbutamol Sulphate and Ipratropium Bromide are probably excreted in breast milk and their effects on neonates are not known. Although lipid-insoluble quaternary bases pass into breast milk, it is unlikely that this will happen to any extent especially when taken by inhalation. However, because many drugs are excreted in breast milk, caution should be exercised when Windel Plus is administered to a nursing woman.
The concurrent administration of other beta-mimetics, systemically absorbed anticholinergics and xanthine derivatives may increase the side effects.
Beta-agonist induced hypokalaemia may be increased by concomitant treatment with xanthine derivatives, glucocorticosteroids and diuretics. This should be taken into account particularly in patients with severe airway obstruction.
Hypokalaemia may result in an increased susceptibility to arrhythmias in patients receiving digoxin. It is recommended that serum potassium levels be monitored in such situations.
A potentially serious reduction in bronchodilator effect may occur during concurrent administration of beta-blockers.
Beta-adrenergic agonists should be administered with caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants, since the action of beta-adrenergic agonists may be enhanced.
Inhalation of halogenated hydrocarbon anaesthetics such as halothane, trichloroethylene and enflurane may increase the susceptibility to the cardiovascular effects of beta-agonists.
The effects of overdosage are expected to be primarily related to Salbutamol because acute overdosage with Ipratropium Bromide is unlikely as it is not well absorbed systemically after inhalation or oral administration.
Manifestations of overdosage with Salbutamol may include tachycardia, anginal pain, hypertension, hypotension , palpitations, tremor, widening of the pulse pressure, arrhythmia and flushing.
Administration of sedatives, tranquillisers.
In severe cases, intensive therapy.
Beta-receptor blockers, preferably beta1-selective, are suitable as specific antidotes; however, a possible increase in bronchial obstruction must be taken into account and the dose should be adjusted carefully in patients suffering from bronchial asthma.
Store below 30°C (86°F).
Windel Plus®: Each box contains 10 ampoules in blister packs.
Products from the same therapeutic group
Theophylline BP 300 mg & 400 mg sustained release tablet
Levosalbutamol Sulphate INN
Salbutamol Sulphate BP
Levosalbutamol Hydrochloride INN
Ipratropium Bromide BP
Roflumilast 0.5 mg (500 mcg) Tablet
Budesonide and Formoterol Fumarate Dihydrate Convicap
Fluticasone Propionate BP and Salmeterol Xinafoate BP inhalation powder.
Salbutamol Sulphate BP inhalation powder.
Leukotriene Receptor Antagonist
Drugs for Allergic Rhinitis
Nasal Steroidal Preparation
Mast Cell Stabiliser
Nasal Decongestant & Mast Cell Combination